Susquehanna International Group
CLDX icon

Susquehanna International Group’s Celldex Therapeutics CLDX Stock Holding History

Susquehanna International Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Buy
53,700
+9,100
+20% +$248K ﹤0.01% 6553
2025
Q4 		$1.21M Buy
44,600
+11,900
+36% +$313K ﹤0.01% 6749
2025
Q3 		$846K Buy
32,700
+1,100
+3% +$25.5K ﹤0.01% 7743
2025
Q2 		$643K Buy
31,600
+18,000
+132% +$350K ﹤0.01% 8585
2025
Q1 		$247K Sell
13,600
-89,900
-87% -$2.01M ﹤0.01% 10498
2024
Q4 		$2.62M Sell
103,500
-4,500
-4% -$122K ﹤0.01% 4724
2024
Q3 		$3.67M Buy
108,000
+66,300
+159% +$2.53M ﹤0.01% 4163
2024
Q2 		$1.54M Sell
41,700
-10,200
-20% -$385K ﹤0.01% 5613
2024
Q1 		$2.18M Sell
51,900
-85,800
-62% -$3.52M ﹤0.01% 5131
2023
Q4 		$5.46M Sell
137,700
-50,300
-27% -$1.48M ﹤0.01% 3556
2023
Q3 		$5.17M Buy
188,000
+102,600
+120% +$3.22M ﹤0.01% 3458
2023
Q2 		$2.9M Sell
85,400
-181,300
-68% -$6.11M ﹤0.01% 4428
2023
Q1 		$9.6M Buy
266,700
+141,200
+113% +$6.09M ﹤0.01% 2514
2022
Q4 		$5.59M Buy
125,500
+25,800
+26% +$921K ﹤0.01% 3070
2022
Q3 		$2.8M Sell
99,700
-288,100
-74% -$8.83M ﹤0.01% 4218
2022
Q2 		$10.5M Buy
387,800
+188,900
+95% +$5.49M ﹤0.01% 2147
2022
Q1 		$6.78M Sell
198,900
-179,000
-47% -$5.72M ﹤0.01% 3140
2021
Q4 		$14.6M Buy
377,900
+13,900
+4% +$606K ﹤0.01% 2217
2021
Q3 		$19.7M Buy
364,000
+96,600
+36% +$4.53M ﹤0.01% 1985
2021
Q2 		$8.94M Buy
267,400
+119,500
+81% +$3.28M ﹤0.01% 3088
2021
Q1 		$3.05M Buy
147,900
+137,700
+1,350% +$3.16M ﹤0.01% 4915
2020
Q4 		$179K Sell
10,200
-227,000
-96% -$4.09M ﹤0.01% 10125
2020
Q3 		$3.52M Sell
237,200
-106,500
-31% -$1.25M ﹤0.01% 3600
2020
Q2 		$4.47M Buy
343,700
+331,800
+2,788% +$1.47M ﹤0.01% 3160
2020
Q1 		$20K Buy
11,900
+1,300
+12% +$2.94K ﹤0.01% 9935
2019
Q4 		$24K Sell
10,600
-600
-5% -$1.39K ﹤0.01% 9468
2019
Q3 		$24K Sell
11,200
-18,900
-63% -$43.7K ﹤0.01% 9925
2019
Q2 		$81K Buy
30,100
+2,700
+10% +$9.17K ﹤0.01% 9693
2019
Q1 		$135K Buy
+27,400
New +$144K ﹤0.01% 8121
2018
Q2 		– Sell
-6,653
Closed -$233K – 9661
2018
Q1 		$233K Buy
6,653
+2,340
+54% +$90.7K ﹤0.01% 8070
2017
Q4 		$184K Buy
4,313
+373
+9% +$16K ﹤0.01% 8343
2017
Q3 		$169K Buy
3,940
+1,747
+80% +$65.5K ﹤0.01% 8124
2017
Q2 		$81K Sell
2,193
-974
-31% -$43.1K ﹤0.01% 8776
2017
Q1 		$171K Sell
3,167
-10,506
-77% -$547K ﹤0.01% 8122
2016
Q4 		$726K Sell
13,673
-5,394
-28% -$307K ﹤0.01% 6194
2016
Q3 		$1.16M Sell
19,067
-9,186
-33% -$572K ﹤0.01% 4528
2016
Q2 		$1.86M Buy
28,253
+3,826
+16% +$243K ﹤0.01% 3702
2016
Q1 		$1.39M Buy
24,427
+8,527
+54% +$959K ﹤0.01% 4449
2015
Q4 		$3.74M Buy
15,900
+8,280
+109% +$1.81M ﹤0.01% 2936
2015
Q3 		$1.21M Sell
7,620
-35,853
-82% -$10.1M ﹤0.01% 5304
2015
Q2 		$16.4M Sell
43,473
-20,580
-32% -$8.17M 0.01% 1495
2015
Q1 		$26.8M Buy
64,053
+31,100
+94% +$11.1M 0.01% 1021
2014
Q4 		$9.02M Sell
32,953
-2,307
-7% -$574K ﹤0.01% 2145
2014
Q3 		$6.86M Sell
35,260
-13,373
-27% -$2.91M ﹤0.01% 2578
2014
Q2 		$11.9M Buy
48,633
+14,506
+43% +$3.28M 0.01% 1915
2014
Q1 		$9.04M Buy
34,127
+6,394
+23% +$2.45M ﹤0.01% 2130
2013
Q4 		$10.1M Sell
27,733
-18,060
-39% -$6.96M ﹤0.01% 2062
2013
Q3 		$24.3M Buy
45,793
+29,580
+182% +$10.1M 0.01% 1070
2013
Q2 		$3.8M Buy
+16,213
New +$3.19M ﹤0.01% 2987

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Susquehanna International Group's CLDX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 35,948 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #7542 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CLDX as recently as Q3 2025.

Susquehanna International Group first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $13.3M in Q4 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Susquehanna International Group held 35,948 shares of Celldex Therapeutics worth $1.14M as of Q1 2026.
  • Celldex Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7542 holding.
  • Susquehanna International Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Susquehanna International Group's Celldex Therapeutics position peaked at $13.3M in Q4 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.